Cobenfy

Cobenfy Warnings and Precautions

• Liver monitoring: Liver enzymes and bilirubin should be assessed before starting treatment and as clinically indicated during treatment.
• Cardiac monitoring: Heart rate should be assessed at baseline and as clinically indicated, as Cobenfy can affect heart rate.
• Renal impairment: Not recommended in patients with moderate to severe renal impairment.
• Gastrointestinal effects: Nausea, dyspepsia, and constipation are common; severe or worsening GI symptoms should be evaluated.
• Pregnancy: Limited data are available on use during pregnancy; animal studies showed maternal toxicity.

How to Access Cobenfy in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Cobenfy to India?

Cobenfy (xanomeline and trospium chloride) capsules may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:

• A valid prescription from a qualified psychiatrist
• The patient's diagnostic reports confirming a schizophrenia diagnosis
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.

Is Cobenfy available in India?

Cobenfy (xanomeline and trospium chloride capsules) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Cobenfy is not commercially marketed in India.

However, patients in India can legally access Cobenfy through the Named Patient Program (NPP) — an import provision that allows patients to receive medicines approved in other countries but not yet marketed in India, under a doctor's prescription and proper regulatory documentation.

Cobenfy received US FDA approval in September 2024 for the treatment of schizophrenia in adults, ensuring full transparency throughout the process.

Cobenfy can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.

Sourcing & Delivery of Cobenfy

Cobenfy is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant logistics to preserve product integrity from dispatch to delivery.

• Storage maintained at 15°C to 30°C throughout transit
• Real-time shipment tracking and delivery updates
• Delivery coordinated directly with the patient, family, or treating hospital

Availability of Cobenfy Across Major Cities in India

Named Patient Program supports access to Cobenfy for patients with schizophrenia across major cities in India, coordinating documentation, sourcing, and delivery with treating psychiatrists.

Mumbai

Patients in Mumbai can access Cobenfy through NPP with support from treating psychiatrists at the city's leading mental health centers.

Delhi

In Delhi, NPP coordinates with hospitals and specialty psychiatry clinics to facilitate timely access to Cobenfy.

Bangalore

Bangalore's psychiatry centers work with NPP to support patients requiring Cobenfy.

Chennai

Patients in Chennai can access Cobenfy through NPP, with coordination between treating doctors and the program's regulatory and logistics team.

Hyderabad

Hyderabad's psychiatry centers support diagnosis and access coordination for Cobenfy through NPP.

Kolkata

NPP facilitates access to Cobenfy for patients in Kolkata under the guidance of treating psychiatrists.

Pune

Patients in Pune can access Cobenfy through NPP with prescription-based coordination and delivery support.

Ahmedabad

NPP supports access to Cobenfy for patients in Ahmedabad, working directly with treating specialists.

Kochi

Patients in Kochi and across Kerala can access Cobenfy through NPP's regulated import pathway.

Chandigarh

NPP coordinates access to Cobenfy for patients in Chandigarh and the surrounding region.

Jaipur

Patients in Jaipur can access Cobenfy through NPP with support from treating psychiatrists.

Lucknow

NPP facilitates access to Cobenfy for patients in Lucknow and across Uttar Pradesh.

Bhubaneswar

Patients in Bhubaneswar can access Cobenfy through NPP's coordinated import and delivery process.

Guwahati

NPP supports access to Cobenfy for patients in Guwahati and across the Northeast region.

NPP also supports access for patients in other Indian cities not listed above — contact the team to check availability and timelines for your location.